Last edition
News about
Boehringer Ingelheim Inks Second Pact with 3T Biosciences to Develop Cancer Immunotherapies
This second research partnership with 3T builds on the successful completion of the initial research partnership announced last year by the two companies.
Geneseeq's CanScan Earns FDA Breakthrough Designation for Advanced Cancer Detection
This cutting-edge technology utilizes low-depth whole-genome sequencing on circulating cell-free DNA, demonstrating an impressive 99 percent specificity in identifying early cancer signals.
Lupin Gets Tentative Approval from U.S. FDA for Dapagliflozin and Saxagliptin Tablets
Dapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Immunexpress Receives FDA Clearance for EDTA Blood-Compatible Cartridges for SeptiCyte RAPID
The inclusion of undiluted EDTA blood as a validated sample type is expected to enhance the utility of SeptiCyte RAPID® in the US clinical setting.
WuXi XDC Enters into Partnership Agreement with IntoCell
Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins.
Hi-Tech Pharmaceuticals adds (4) more Stokes 328 tablet presses to increase our ability to make more large tablets for our Cyclosome® Technology and Guaifenesin OTC drug products.
PillSafe Launches 'Smart' Pill Bottle for Prescription Drugs
PillSafe® uses new disruptive technology, a groundbreaking economical “smart” pill bottle for prescription drugs, designed by doctors to ensure safety and compliance with medication in the fight against addictive drugs.
MediLink Therapeutics and Roche Announces Worldwide Collaboration and License Agreement
MediLink Therapeutics have announced that it has entered into a worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumours.
Glenmark is First to Launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
Glenmark Pharmaceuticals Ltd. has launched a biosimilar of the popular10,11 anti?diabetic drug, Liraglutide, for the first time in India.
Renovos Biologics Awarded FDA Breakthrough Device Designation for RENOVITE BMP-2
The breakthrough designation is a recognition of RENOVITE® BMP-2's potential to provide more effective diagnosis and treatment for conditions related to bone regeneration.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy